Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 17/20 | 0.53 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14157699 | 1.00 | RAB9A (0.56) | RAB9AKDM4EMAPTAGTR1OPRK1 | |
| SCHEMBL2591243 | 0.84 | HSD11B1 (0.70) | HSD11B1 | |
| SCHEMBL14157595 | 0.84 | HSD11B1 (0.52) | HSD11B1HSD11B2 | |
| SCHEMBL15706725 | 0.84 | HSD11B1 (0.52) | HSD11B1HSD11B2 | |
| SCHEMBL15706767 | 0.82 | HSD11B1 (0.52) | HSD11B1HSD11B2 | |
| SCHEMBL14157736 | 0.82 | HSD11B1 (0.52) | HSD11B1HSD11B2 | |
| SCHEMBL15706762 | 0.81 | HSD11B1 (0.52) | HSD11B1HSD11B2 | |
| SCHEMBL14157705 | 0.81 | HSD11B1 (0.52) | HSD11B1HSD11B2 | |
| SCHEMBL3455510 | 0.81 | GRM5 (0.58) | RAB9AKDM4EMAPTAGTR1OPRK1 | |
| SCHEMBL14157666 | 0.81 | HSD11B1 (0.53) | MAPTHSD11B1HSD11B2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233957-B2 | 5-carbamoyl-adamantan-2-yl amide derivatives, pharmaceutically acceptable salts thereof and preparation process thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-01-12 | — | — | US | disclosed |
| US-20140128427-A1 | 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128427-A1 | 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF | HSD3B1, HSD11B1, HSD3B2 | RAB9A 759/4885KDM4E 1013/4885MAPT 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.